PET scans may help guide chemo for rare abdominal cancer
NCT ID NCT04224948
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether PET scans can detect early response to chemotherapy in people with retroperitoneal sarcoma, a rare cancer in the abdomen. 18 participants received extra PET scans before and after their first chemo cycle. The goal was to see if PET could predict tumor shrinkage better than standard CT scans, which take longer to show results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PET MRI scan
- What this could lead to
- If PET scans prove reliable, doctors could adjust chemotherapy earlier for sarcoma patients, potentially improving outcomes.
- What could go wrong
- This is a very small, early study (18 people) focused on imaging accuracy, not treatment. It may not change practice or benefit patients directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE DEDIFFERENTIATED LIPOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Health Network and The Sinai Health System
Toronto, Ontario, M5G 1X5, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Electric shocks + chemo: new hope for inoperable tumors?
- Could chemo before surgery beat sarcoma? new trial aims to find out
- 800-Patient study aims to tailor sarcoma treatment
- New combo therapy aims to improve sarcoma surgery outcomes
- Double dose of numbing drug may slash opioid need after sarcoma surgery
- New radiation method aims to improve sarcoma surgery outcomes